Intervacc’s developmental program for new vaccines against animal infectious diseases is summarised in the following table. Please, click on respective project name or indication to read more.
|INV274||Strep. suis infection||Piglets|
|INV412||Staph. aureus mastitis||Cow|
The successful clinical trials with vaccination against strangles using Strangvac®, based on fusions of recombinant proteins, demonstrates that our technology can be applied also for development of other vaccines. In contrast to conventional vaccines, using attenuated live strains, our technology using recombinant proteins as antigens results in a safe and efficacious vaccine with very low incidence of unwanted side effects.